Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 4/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 2/20 | 0.40 |
| ▸ | AHR | P35869 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29438605 | 0.89 | CA9 (0.62) | MAPTCA9MAOAMAOBNPC1 | |
| SCHEMBL8751 | 0.89 | CA9 (0.62) | MAPTCA9MAOAMAOBNPC1 | |
| SCHEMBL6405990 | 0.86 | MAPT (0.58) | MAPTMAOAMAOBPRKCINPC1 | |
| SCHEMBL29946465 | 0.86 | MAPT (0.58) | MAPTMAOAMAOBPRKCINPC1 | |
| SCHEMBL28979239 | 0.82 | MAPT (0.53) | MAPTMAOAMAOBPRKCINPC1 | |
| SCHEMBL14188941 | 0.81 | CA9 (0.45) | MAPTCA9MAOAMAOBNPC1 | |
| SCHEMBL7505614 | 0.80 | MAPT (0.59) | MAPTCA9NPC1MAPK13MAPK12 | |
| SCHEMBL31478025 | 0.79 | AHR (0.61) | CA9MAOAMAOBCRBNCMA1 | |
| SCHEMBL1833499 | 0.79 | AHR (0.61) | CA9MAOAMAOBCRBNCMA1 | |
| SCHEMBL7428888 | 0.79 | MAPT (0.58) | MAPTCA9MAOAMAOBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528160-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528160-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528160-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1869041-A1 | TETRAHYDRO-PYRIDOAZEPIN-8-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20060234997-A1 | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2006-10-19 | — | — | US | disclosed |
| WO-2006103559-A1 | TETRAHYDRO-PYRIDOAZEPIN-8-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006103559-A1 | TETRAHYDRO-PYRIDOAZEPIN-8-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | disclosed |
| US-20050234041-A1 | Substituted 1-benzazepines and derivatives thereof | BIOPORT R&D, INC. | 2005-10-20 | — | — | US | disclosed |
| EP-1392317-A4 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | ANTEXPHARMA INC (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-1581521-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1229913-A4 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | ANTEXPHARMA INC (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2004063190-A1 | FUSED HETEROCYCLIC DERIVATES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| EP-1392317-A2 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | Antexpharma, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-6514965-B1 | For treating bacterial infections | ANTEX PHARMA INC. | 2003-02-04 | — | — | US | disclosed |
| WO-2002100327-A2 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | ANTEXPHARMA, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-1229913-A1 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | Antexpharma, Inc. (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001035964-A1 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | ANTEXPHARMA, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060234997-A1 | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | PTGDR, GRIN2A, PTGDR2 | MAPT 2060/4885CA9 4646/4885MAOA 19/4885 |
| US-20050234041-A1 | Substituted 1-benzazepines and derivatives thereof | BAK1, BAD, BAX | MAPT 2956/4885CA9 4276/4885MAOA 145/4885 |
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | PPARG, PPARA, PPARD | MAPT 3515/4885CA9 4140/4885MAOA 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.